Acelyrin says CRO Fortrea made errors in trial of lead immunology drug izokibep

Ace­lyrin said a con­tract re­search or­ga­ni­za­tion con­duct­ing stud­ies of its lead ex­per­i­men­tal drug had made “clin­i­cal tri­al ex­e­cu­tion er­rors” and it was con­duct­ing an au­dit of the work, a set­back that’s like­ly to cost the biotech time and mon­ey.

Mon­day af­ter­noon’s an­nounce­ment is bit­ter news for the com­pa­ny, which went pub­lic in May and raised $540 mil­lion, on­ly to see its stock crater af­ter the drug, an IL-17A in­hibitor named izok­ibep, failed in a tri­al of pa­tients with hidradeni­tis sup­pu­ra­ti­va ear­li­er this fall.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.